Welcome!

News Feed Item

China Heparin Industry Report, 2012-2014

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Heparin Industry Report, 2012-2014
http://www.reportlinker.com/p0354148/China-Heparin-Industry-Report-2012-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

China, abundant in heparin raw materials, has become one of the world's largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China's export volume of heparin API was no more than 105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period.

Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of China's total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of China's top 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by 3.8% and 2.1% year-on-year respectively in Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinal number of exported prices in the preceding year.

Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand.

Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011.

However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%.

Table of Contents
1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2. Operating Environment of Chinese Heparin Industry
2.1 Entry Barriers
2.1.1 Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Supply and Demand in Global Market
2.3 Competition in Global Market
2.4 Global Market Forecast

3. Development of Heparin API Industry in China
3.1 Market Status Quo
3.2 Market Supply and Demand
3.3 Competitive Landscape
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Outlook & Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Competition Pattern
4.3 Market Segments
4.3.1 Low Molecular Weight Heparin Preparation
4.3.2 General Heparin Preparation
4.4 Development Outlook & Forecast

5. Key Chinese Heparin Manufacturers
5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Prospects
5.2 Changzhou Qianhong Bio-Pharma Co., Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Prospects
5.3 Yantai Dongcheng Biochemicals Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Clients and Suppliers
5.3.7 Heparin Business
5.3.8 Prospects
5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Prospects
5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Prospects
5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
5.6.1 Profile
5.6.2 Operation and Prospects
5.7 Wanbang Biopharmaceuticals
5.7.1 Profile
5.7.2 Operation and Prospects

Selected Charts

Application of Heparin Preparations
Heparin Industry Chain
Difference between Heparin Sodium API and Heparin Standardized Requirements
Heparin Preparation Market Scale and YoY Growth Worldwide, 2006-2011
Performance: Low Molecular Weight Heparin Preparation vs. General Heparin Preparation
Global Heparin Preparation Distribution by Region, 2011
Heparin API Demand and YoY Growth Worldwide, 2007-2011
Sales of Enoxaparin Worldwide by Product, 2010-2012
Regulatory Exclusivity of Lovenox, as of late 2011
Global Heparin Preparation Market Scale, 2011-2014E
Global Heparin API Demand, 2011-2014E
Gross Margin of Major Heparin API Manufacturers in China, 2008-2012
Capacity of Crude Heparin in China, 2009-2011
Average Export Price of Heparin and Heparinate, 2008-2012
Capacity of Major Heparin API Manufacturers in China, as of June 2012
Export Volume and Export Value of Heparin and Heparinate in China, 2008-2012
Export Price of Heparin and Heparinate in China, 2008-2012
Top 10 Export Destinations of Heparin and Heparinate in China by Value, 2011-2012
Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011
Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012
Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, 2008-2011
Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012
Heparin Preparation Market Scale and YoY Growth of China, 2007-2011
Market Share of Heparin Preparation Products in China, 2011
Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China
Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations
China Low Molecular Weight Heparin Preparation Market Scale, 2009-2011
Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals, 2010-2011
Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22 Chinese Cities, 2010-2011
Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009
Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009
China Heparin Preparation Market Scale and YoY Growth, 2011-2014
Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1
Revenue and Profit of Hepalink, 2008-2012
Revenue of Hepalink by Product, 2008-2012
Revenue of Hepalink by Region, 2008-2012
Gross Margin of Hepalink by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hepalink, 2009-2011
Revenue of Hepalink from the Top 5 Clients and Proportion, 2008-2012
Revenue and Operating Income of Hepalink, 2011-2014E
Assets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1
Revenue and Profit of Qianhong Bio-Pharma, 2008-2012
Revenue of Qianhong Bio-Pharma by Product, 2008-2012
Revenue of Qianhong Bio-Pharma by Region, 2008-2012
Gross Margin of Qianhong Bio-Pharma by Product, 2008-2012
R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, 2009-2011
Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012
Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011
Purchase Value of Qianhong Bio-Pharma's Top 5 Suppliers and Revenue Contribution of Qianhong Bio-Pharma's Top 5 Clients, 2009-2012
Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, 2008-2012
Revenue and Operating Income of Qianhong Bio-Pharma, 2011-2014
Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1
Revenue and Profit of Dongcheng Biochemicals, 2008-2012
Revenue of Dongcheng Biochemicals by Product, 2008-2012
Revenue of Dongcheng Biochemicals by Region, 2008-2012
Gross Margin of Dongcheng Biochemicals by Product, 2008-2012
R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, 2008-2012
Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals, 2008-2012
Heparin Sodium API Price of Dongcheng Biochemicals, 2009-2011
Revenue Contribution of Dongcheng Biochemicals' Top 5 Heparin Sodium API Clients, 2009-2011
Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, 2013-2015E
Revenue and Profit of Dongcheng Biochemicals, 2011-2014E
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, 2008-2012
Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical, 2009-2011
Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei Changshan Biochemical Pharmaceutical, 2011
Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as of late 2011
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2011-2014E
Revenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Region, 2008-2012
Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, 2009-2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase Sun Pharmaceutical, 2011
Name List, Purchase Value and Proportion of Top 5 Suppliers of Tianjin Chase Sun Pharmaceutical, 2011
Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, 2011-2014
Assets and Net Income of Wanbang Biopharmaceuticals, 2008-2011


To order this report:
Pharmaceutical Industry:
China Heparin Industry Report, 2012-2014

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
In this presentation, Striim CTO and founder Steve Wilkes will discuss practical strategies for counteracting fraud and cyberattacks by leveraging real-time streaming analytics. In his session at @ThingsExpo, Steve Wilkes, Founder and Chief Technology Officer at Striim, will provide a detailed look into leveraging streaming data management to correlate events in real time, and identify potential breaches across IoT and non-IoT systems throughout the enterprise. Strategies for processing massive ...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
"We focus on composable infrastructure. Composable infrastructure has been named by companies like Gartner as the evolution of the IT infrastructure where everything is now driven by software," explained Bruno Andrade, CEO and Founder of HTBase, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Cloud Academy named "Bronze Sponsor" of 21st International Cloud Expo which will take place October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara, CA. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud com...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.